These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7695248

  • 1. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.
    Entenza JM, Blatter M, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2683-8. PubMed ID: 7695248
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
    Entenza JM, Caldelari I, Glauser MP, Moreillon P.
    J Antimicrob Chemother; 1999 Dec; 44(6):775-86. PubMed ID: 10590278
    [Abstract] [Full Text] [Related]

  • 4. Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.
    Blatter M, Fluckiger U, Entenza J, Glauser MP, Francioli P.
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1971-6. PubMed ID: 8239615
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations.
    Cremieux AC, Saleh-Mghir A, Vallois JM, Maziere B, Muffat-Joly M, Devine C, Bouvet A, Pocidalo JJ, Carbon C.
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2216-21. PubMed ID: 1332590
    [Abstract] [Full Text] [Related]

  • 6. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Maserati R, Cagni AE, Segú C.
    Chemotherapy; 1996 Oct; 42(2):133-9. PubMed ID: 8697888
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
    Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J, Pocidalo JJ.
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2698-703. PubMed ID: 1336343
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
    Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
    López Fornas F, Martínez García F, Pérez Salmeron J, Roldán Conesa D, Cortés Sanchez R, García Alberola A, Ruíz Gómez J, Gómez Gómez J, Valdés Chávarri M.
    J Antimicrob Chemother; 2001 May; 47(5):623-9. PubMed ID: 11328774
    [Abstract] [Full Text] [Related]

  • 10. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
    [Abstract] [Full Text] [Related]

  • 11. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci.
    Shelburne SA, Greenberg SB, Aslam S, Tweardy DJ.
    J Infect; 2007 Feb; 54(2):e99-101. PubMed ID: 16824611
    [Abstract] [Full Text] [Related]

  • 12. Effect of gentamicin dosing interval on efficacy of penicillin or ceftriaxone treatment of experimental endocarditis due to penicillin-susceptible, ceftriaxone-tolerant viridans group streptococci.
    Brandt CM, Warner CB, Rouse MS, Steckelberg JM, Wilson WR.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2901-3. PubMed ID: 9124865
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [Abstract] [Full Text] [Related]

  • 18. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB, Lin G, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.